top question manag team
life scienc tool diagnost sector review
ahead annual credit suiss healthcar confer scottsdal az next
week nov compil list relev question topic discuss
respect manag team across divers coverag univers life scienc tool
diagnost compani emphasi follow sub-sector anim health contract
servic organ clinic laboratori dental life scienc drug distributor
among other pleas reach team copi latest model request
prepar meet
need brace clear align market primer
anim track chew vet survey
hand rein
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
compani data credit suiss factset million except per share data
base factset consensu estim se estim
tabl content
labcorp america lh
break-out quantifi factor contribut asp pressur fx vs mix
shift updat think asp trend longer term
speak new consum orient market activ strategi
tv vs on-line vs print teen vs adult exactli campaign start
success consumer-ori market campaign to-dat
measur success newer market effort expect elev
level market spend continu longer term
term doctor-ori effort promot leverag
directli price concess bundl co-market
broader macro perspect speak sensit across busi
potenti volatil macro environ
think season across domest vs variou intern market
growth china meaning better anticip
expect support elev growth china longer term longer term growth outlook
growth target dwarf lst peer coverag univers
help us get comfort lt outlook light growth retreat
lower end guid past sever quarter conservative/achiev
lt target key underli driver
think margin trajectori next sever quarter
ramp new china manufactur facil variou treatment plan facil
salesforc invest litig expens anticip
think longer term oper margin target
restructur effort better posit lt tax advantag
youv highlight past relationship aspen dental heartland dental
speak dso strategi would character discuss
give us updat third-parti financ initi econom behind
offer key growth driver longer term traction
updat develop pipelin hole still look fill
palat expand focus develop product ortho
think spend come quarter longer term
capit deploy prioriti philosophi type asset might make sens
larg deal would compani consid
speak doctor-l invisalign experi locat mani locat
current econom work traction
non-compet end establish direct consum clear align compani
expect open own invisalign store similar previou
strategi
sever industri constitu launch clear align offer us
other reaction new entrant provid updat
competit environ evolv sinc launch new offer
straumman clearcorrect product compar invisalign
think potenti impact launch market intern
import recently/ upcom patent expiri limit competitor particip
market vs extent barrier entri driven deep market
penetr market capabl
think threat competit direct consum clear align
busi quantifi overlap
sinc began ship mandibular advanc us long
take contribut meaning result roll-out typic look like
type newli launch product
speak notabl slowdown volum growth north america past
coupl quarter view key driver new normal
traction invisalign first feedback thu far
roll-out brazil broader traction market opportun
traction see smile concierg servic launch last year
speak opportun retail concept walgreen
rate would expect grow number new doctor balanc
year would estim current penetr potenti doctor us vs
region
ad new doctor long typic take see meaning case volum
ramp similar averag level product rule appli
doctor prescrib case
sustain rapid growth china driver across geographi
updat approval/launch palat expand
experienc growth itero revenu follow
break driver itero growth expect growth trend
remaind year beyond
speak relationship glidewel dental overal distribut
strategi itero
receiv china fda approv sell itero element china speak
china strategi penetr trend relat itero scanner
opportun exist market
updat global distribut agreement itero element zimmer biomet
timing/magnitude/feedback associ launch new itero cari screen
intern updat time us approv
conjunct report rais intern revenu growth expect
upper end speak driver area conservat potenti
youv re-affirmed long term target impli bp margin expans
top-line growth walk us strategi
help us get comfort viabil goal given meaning ramp
experienc strength consum past quarter albeit easi comp
would character underli domest demand trend across consum
think consum growth light new product launch lap
revenu benefit venlo facil disrupt shift
dentsply-sirona day launch one ds
equip experienc robust growth innov lap destock
dynam would character underli demand trend equip
think growth dynam
dental practic traffic trend end-us demand us base observ
convers distributor
provid color recent launch one ds promot program
launch octob exactli work feedback thu far
outlin demand dynam across europ broader intern market
particular market experienc strengthen demand
impli guidanc term demand trend europ
demand trend lt growth rate gener vs specialti consum
relationship penetr dso account direct relationship
million destock step taken gain better
visibl distribut channel
supplier relationship progress also give us updat
salesforc effici initi ramp us expect increas direct
youv post sizeabl billion charg date respect siro merger
help us understand charg view term strateg
rational merger adopt chang plan growth
combin compani competit posit technolog
cad/cam strategi evolv sinc ceo casey come board
cad/cam recent launch primescan differ omnicam
offer competit offer product receiv thu far
pushback price
view new open-architectur approach help address previou key barrier
omnicam broader cad/cam adopt cad/cam penetr stand
today go longer term
primescan anticip greater adopt new user upgrad
upgrad program perform to-dat launch octob think
potenti revenu growth impact program
call spoke develop comprehens imag portfolio
speak hole look fill area invest
speak recent launch implant system astra
product fit within broader implant portfolio differenti product
thought implant strategi broadli market share
provid updat discuss align technolog obtain
interoper primescan invisalign would character upsid
thought recent launch suresmil clear align product
differenti offer market
view market opportun clear align space given
competitor also recent enter space well one domin player help us
understand model opportun tam
target million net cost save think
key compon annual cadenc save initi room
upsid target
mention redirect spend area product categori
view compel could reinvigor growth
speak initi progress youv made thu far salesforc
execut effort roll-out new sale structur progress us
anticip new structur impact result help us
think roll-out geographi time
success drive better effici measur
term portfolio trim speak rational behind portfolio trim
activ come much go current sku count
state capit deploy prioriti level leverag
comfort stretch balanc sheet right opportun
activ share buy-back qtd level share repurchas
embed guidanc
amazon sort shift either direct third-parti distribut provid
late lot chatter industri whether on-line retail may
provid viabl altern tradit distributor consum side
busi stanc issu
updat sec document request disclos previou file
adjust new stand-alone public compani compar
histor oper umbrella
speak revenu growth algorithm volum vs price equip
consum vs specialti expect improv organ revenu growth
essenti flat today lsd msd longer term
youv comment consolid effort past sever year
highlight step taken drive effect innov
success translat new product launch
speak dealer-partn relationship commit util
tradit distribut compar direct sale effort expect sale
convent distribut sale evolv time
past coupl year point destock dynam headwind
core growth extent visibl channel stock level
step taken improv channel visibl
dental servic organ dso strategi also help us think
margin dynam relationship
achiev double-digit growth china high-growth market overal appear
weak pars underli dynam
outlin demand dynam across europ broader intern market
particular market experienc strengthen demand
impli guidanc term demand trend europ
would character underli demand consum north america
equip trend north america sell-out trend
core equip growth declin mid-singl digit rang pars
underli driver weak imag vs treatment unit vs equip
drive convict equip improv
tradit equip consum segment weak organ basi
last year growth segment go next five year
strategi acceler growth
intraor imag becom increas focu across dental market area
notic absent expect launch kavo
differenti offer rel current offer market
thought chairsid cad/cam offer expect enter
intraor imag key area focu innov perspect
across equip consum categori
implant market share today across premium valu market
speak histor market share shift experienc expect
share market go time
experienc bp headwind discontinu oper transform
effort relat valu implant busi transform effort start
headwind impact roll
histor premium valu implant brand compet
implant strategi chang past year brand
perform sinc strategi shift nobel biocar implant direct logon alphabio
recent announc implant system offer differenti rel
alreadi market price strategi feedback to-dat
product contribut meaning top-line growth
spark clear align broader strategi spark perform
market fulli launch product australia feedback
spark pilot us pilot perform to-dat
expect fulli launch system us price market expect
expand next twelv month
could launch spark clear align impact growth trajectori
convent bracket wire offer success coexist
ebit margin expans well street expect pars
underli dynam drive margin perform quarter
discuss envista busi system philosophi provid
exampl driven enhanc revenu growth cost save
extent target million cost save fall bottom
line vs reinvest cadenc synergi
think longer term margin expans opportun
think oper margin go time
term type compani offer look bolt-on vs new
thought around implement dividend thought around time
level share repurchas embed guidanc activ
much dental consum growth attribut underli market
dynam vs market share gains/loss see current market growth
rate consum na market sort visibl underli
consum demand trend across dental busi
think north america dental consum growth trend head
longer term guidanc assum term underli demand
term intern consum growth unpack dynam
across variou geographi particular bright spot surpris
think longer term growth opportun intern consum
specialti highlight bright spot intern growth speak
market posit across specialti categori expect differ
categori grow go forward level invest ortho implant
unpack america equip intern sale growth particularli
follow declin impact shift dentspli sirona world
vs underli driver lt equip growth
would character abil line sight margin expans next
speak one earli result ventur far demand
gener strategi expand adopt across practic
describ relationship differ across dso henri
schein one fit relationship
detail/provid background dso formulari manag effort
servic provid regard anticip abl
command price
updat dso re-contract head long contract typic
speak increment invest allud call
relationship distribut
seen evid greater direct sale initi manufactur
anyth chang increment posit neg relat opportun
sirona relationship rel initi expect
think emerg market strategi recent acquisit china
distributor thailand growth opportun brazil
amazon lot nois industri whether on-line retail may
provid viabl altern tradit distributor consum side
busi stanc issu amazon market share
initi thought xray new cerec primescan trio launch
remind us strategi relat proprietari product brand area
interest invest product better posit market
speak strength experienc implant term
premium versu valu growth come current
see greatest opportun
think strateg rational rel recent invest
three implant busi intra-lock medenti medic pro-cam
competit posit implant
speak reveal clear align system compar slx
product differenti product current expect
market plan posit product price traction assum
believ market opportun clear align segment given
clear domin player space conjunct least two
competitor enter space strateg rational enter market
youv note lack softwar penetr germani prevent bring
current offer germani best pathway gain foothold
speak broader sale trend chairsid vs stand-alone digit impress
seem disconnect underli util demand trend medic
report attribut share gain much runway
continu captur market share
provid color around recent trend medic see major
driver risk factor head
opportun one medic
margin differ medic dental give us sens
product mix medic highest margin product
key driver rel faster growth medic despit low volum
note paid credit facil cash inflow
think capit deploy light stronger balanc sheet
appetit larger deal
type deal interest pursu medic vs dental bolt-on vs
youv previous guid million tsa revenu still
line current think tsa revenu million recogn
help us think profit across gross margin
call spoke sale minor invest octob
embed guidanc help us think impact
well impact thereon minor interest
speak drive growth technolog value-
ad servic segment think growth trajectori nt
youv mention push sell higher margin privat label product talk
associ initi percentag current sale
youv previous spoken balanc necessari busi invest margin
stabil provid insight plan
invest plan priorit
talk sale forc initi develop
think current capit deploy prioriti de-lever share
would character current pipelin across dental anim health
gap offer product and/or geograph perspect size
potenti deal
speak broader opportun privat label across dental veterinari
new ancillari busi unit would interest implant product pim
speak progress erp implement help enhanc
e-commerc effort larg public competitor state
total sale e-commerc significantli higher consum
stack rel
speak end market demand trend quarter dental
see qtd expect come quarter
balanc
year
stocking/destock dynam new product launch manufactur dentspli
think equip sale
sort visibl underli consum demand trend across
dental busi expect consum growth turn posit
pos po price pressur note headwind previous
provid updat see market see pressur
consum equip side headwind evolv
past year would mitigate/exacerb trend
opportun better penetr dso dso strategi would
character current price environ
quantifi consum purchas associ practic
purchas cerec unit sort shift seen block market sinc
chang sirona relationship
heartland dental relationship gone thu far sale rel
new custom gener line initi expect expect see
pickup equip demand custom expand dental
would character growth differenti tradit dental practic
dso pro con work dso
abl win addit busi front late
quantifi impact ad new dental technolog product xray
new primescan think sale mix could ultim evolv
new product upgrad cycl tailwind
anyth chang increment posit neg relat opportun
within dental technolog outsid rel initi expect
comment recent aggress price across imag platform
equip financ dental help us think flow
 think go forward
amazon lot chatter industri whether on-line retail may
provid viabl altern tradit distributor consum side
busi stanc issu envis amazon meaning
competitor longer term current market share
help us think underli factor affect vet oper margin
expans think oper margin go forward longer term
speak revenu mix companion vs product anim evolv
time expect go futur mix current
talk henri schein anim health vet first choic spin/merg
thought merger relationship vetsourc
would similar merger option vetsourc particularli given alreadi
distributor competitor highlight weak companion anim veterinari market
post growth help us understand health
underli market dynam play
pretti signific stake vetsourc view
impact recent direct relationship manufactur e-commerce chewi
expect minim averag price map impact tradit distribut effort
across vet market go forward
feedback hear market vetsourc rel compet
offer vet first choic adopt trend
would contempl competit dynam chang launch tripl
combin parasiticid flea/tick/heartworm exposur parasiticid
product anim side provid updat underli market
dynam qtd drive strength swine market expect
turnaround beef/dairi market
consid conduct strateg review anim health busi
potenti opportun strateg rational retain busi
meaning chang vendor contract calendar year
switch agenc buy/sel
think market misstep help us better understand
newer market strategi implement didnt work extent
convers deterior extent recov
speak broader market strategi tv ad vs social media vs print
suscept experienc setback similar happen
term itero file convers headwind long take realiz file
automat download problem fulli rectifi protocol
put place prevent similar issu go forward
address market percentag potenti custom malocclus
effect treat percentag patient turn away
speak patient demograph mix relat age incom threshold
mani practition suggest clear align offer safe and/or
effect clinic test done demonstr efficaci head-to-head
larg doctor network current requir join doctor network
current doctor capac compar demand room growth doctor
extent smilepay financ improv convers sinc launch
acknowledg smilepay repres sale today expect metric
go time
close bad debt remain meaning higher averag credit card
strategi implement improv metric forese implement
credit check forese futur
walk us sensit analysi relat smilepay financ macro
recent launch new nighttim align offer recept
product thu far expect materi contribut growth
speak senior manag relev experi commit
up-front cost addit smileshop store break cost
us
past two year expand smileshop footprint virtual zero
store go forward mani store expect add annual
expect moder store footprint growth rel
help us think unit econom differenti cvs/walgreen co-
locat store share retail store wework
cvs/walgreen co-loc store locat perform rel share
retail store wework
walgreen relationship progress thu far domest
talk work addit partner
speak intern smileshop strategi expect open
stand-alone store share retail store co-loc store partner locat
speak intern store partnership
march lawsuit align technolog effect forc
close invisalign experi store also extend non-compet
speak outcom litig longer term implic
weve seen numer new dtc entrant space extent view
new player competit threat
candidco appear closest competitor dtc market walk
sdc model offer differenti rel candidco
speak success current intern market includ canada australia
new zealand unit kingdom ireland surpris
broader intern expans strategi plan focu expand
presenc current market continu launch new geographi
intern market anticip expand next year
consid potenti intern expans opportun key factor drive
decis
expect intern revenu total revenu go time
recent pushback practition around sdc abil practic dentistri
dynam refut call dso corpor structur speak
corpor structur implic
implic amicu brief file doj ftc alabama georgia
help us understand implic ab california call
radiograph equival bone-level imag sdc requir put x-ray machin
store
california ab also requir licensur relev doctor inform
disclos patient given practition peer clearli look favor upon sdc
employees/contract could impact doctor network
next step california timelin implement
happen lead point expect address ab
regulatori dynam awar
help us better understand time rational recent ceo transit
search perman ceo progress timelin updat
speak underli driver weak across north america busi
think distribut revenu growth rel grow contribut
vet first choic platform
follow henri schein anim health vet first choic merger form
head hsah north america chose leav help us becom
confid distribut segment nt execut light manag shift
speak expertis matthew leonard new evp presid north america
global suppli chain offic bring
speak privat label strategi expect expand privat label
portfolio meaning think privat label penetr go term
percentag total sale econom compar privat label
third-parti product garner attent product launch
tripl combo repres meaning opportunities/risk
price ration marketplac see competitor includ direct
sale effort manufactur undercut price certain product
expect switch tradit buy/sel relationship agenc transact next
year vice versa meaning million ebitda synergi target
term convert agenc sale platform
speak relationship corpor account see
evolv next sever year comment mars/woof relationship shift
often contract renew nva
current supplier concentr largest supplier
mitig exposur
walk us econom vet first choic platform
receiv vs veterinarian vs manufactur compar vetsourc
platform structur profit dynam vet
speak impact recent effort manufactur establish direct
relationship altern on-line concept
manufactur go direct altern channel constitu chewi theyr
enforc minimum averag price map implic map price
broadli vetsourc often view closest competitor view
posit rel vetsourc see often marketplac see
on-board addit veterinarian
think penetr vet first choic platform
speak activ therapi manag technic repres
add veterinarian platform long take see meaning
contribut ramp typic look like
weve heard chewi potenti plan launch share econom program vet
similar speak posit market light evolv market
mention call focu potenti roll vet first choic
platform intern speak potenti timelin expans
countri look
bridg ebitda guidanc revis previous least
million
help us get comfort dd growth expect beyond
key driver potenti risk
help us think million synergi expect realiz year
acknowledg still earli day synergi captur progress thu far
breakdown
mergers/divestitures/ipo anim health pharmaceut market impact
ipo merger
cost synergi current includ youv combin busi
six month abl identifi increment cost synergi
think margin go overtim
follow two consecut guidanc revis comfort rel debt
coven call net debt net debt stand current
think growth run-rat geographi north america europ
would character current fundament dynam companion anim
market thought vet util trend pet ownership trend spend per pet
explain flow fx gross margin oper margin line
anticip term fx top-line profit perspect
total exposur product anim unit state abroad
speak see product anim busi relat
contraction/expans cattl herd size feed cost cattl feed relev
variabl see swine market poultri
speak transit servic agreement tsa
impact servic tsa includ
updat season trend flea/tick season global cattl herd trend
capit alloc strategi near term capac desir
engag near term prioriti primarili debt pay
would character current veterinari demand trend qtd reflect
guidanc longer term assumpt relat fundament demand
recent rais lower end organ growth outlook
primari driver revis
term preliminari guidanc speak underli
driver across dx lpd element conservat potenti risk
given ceo transit expens north america field forc expans
two new facil come on-lin think cadenc
margin expans bp ex ceo transit impact
sustain price dynam
quantifi overal nt lt opportun associ prevent care
initi primari barrier unlock valu sort initi
implement address tangibl datapoint track progress
much custom base use refer laboratori point care
dual-mod overlap trend metric go time
driver practic volum revenu strength track system
room run term broader demand growth util us
speak recent trend same-stor vet offic visit clinic visit practic
revenu base data track recent chang calcul methodolog
speak initi econom broader roll-out
sdma slide perform impress expect
contribut consum growth ramp time competitor wing
sedivu provid updat placement trend consum
util track traction compar intern expect
catalyst one see meaning step consum util similar
catalyst dx adopt experi thought core chemistri placement trend nt
equip placement trend quantifi upgrad opportun core chemistri
us typic replac cycl
thought rapid assay competit landscap vs first gener product
 much futur invest equip vs novel test vs
system new area test interest explor unmet need
think implic ztss entranc refer laboratori
market us
continu gain share us refer laboratori updat refer
laboratori competit landscap vs vca regional/academ player
acquir marshfield lab million revenu help us think
strateg ration vs organ invest pipelin updat similar deal
competit bid
think intern refer lab new sale forc effort ramp
refer lab strategi differ rel refer
laboratori strategi us current eu macro environ broader adopt
traction fecal antigen test refer lab
opportun improv refer laboratori profit thought recent dynam
vetconnect pet health network adopt stand
expect impact volum retent rate market share time
opportun better monet data asset
would character adopt trend digit radiographi capit equip
purchas trend vet clinic
rational behind new north america salesforc expans help us think
ramp new salesforc expect achiev optim product
direct distribut approach differ term cross-sel
promot activ bundl across refer lab in-hous
intern geographi target penetr
market today increment opportun better penetr across market
implic covetrus/vetsfirstchoic adopt work
updat relationship corpor account banfield
sustain market share posit growth higher margin segment
product launch new contamin outbreak would character
commit busi
speak key driver across livestock busi exposur lacklust
dairi end market african swine fever competit landscap
think long term growth rate lpd busi see
increment opportun potenti invest bovin genom similar area
lpd segment predominantli intern lpd sale see
opportun domest commit lpd effort
thought ztss acquisit abaxi last year competit landscap
evolv to-dat seen benefit disrupt market
zts/abax deal step taken maintain industri lead posit
may also move direct distribut model diagnost anticip
influenc purchas pattern rapid
decid longer provid longer term pipelin updat
competit respons primarili driven zts/abax transact
abil work veterinari clinic well plan pet health insur util
geograph area focu particularli strong underli veterinari
character on-going dynam product anim demand trend differ
domest intern market
challeng dairi market mention see stabil
give color drive whether think stabil
continu impact omnigen sale
mention pivot dairi strategi gain market share provid
product larg scale cow dairi farm rather cater small dairi
farm give us color strategi progress
updat omnigen traction product
think demand trend across poultri swine dairi next
african swine fever impact china
mention million headwind busi
essenti equat entireti china sale impact seen
date seen offset yet term increas demand
offset market
see benefit larger amount us export pork china
zoeti point new commerci polici cattl brazil headwind
benefit
updat work develop asf vaccin mention
multibillion dollar market size size market
insight possibl timelin
note custom order pattern impact mfa give
color whether think chanc may continu next
talk foray companion anim provid color
expect busi
feel need scale readili compet companion
anim market compet use one-off product
talk in-licens companion anim technolog
platform complet product readi go-to-market
rejensa success far trial distribut period
color timelin top-lin impact product
expect entri companion anim go beyond lyme diseas project
kind project could expect
broadli speak new product current develop key
area invest see meaning opportun certain therapeut
class speci
give color timelin invest strateg initi
think impact beyond spend frontend load
would character underli demand trend categori
headwinds/tailwind incorpor guidanc expect
impli guidanc
expect chang mix profit versu part
world mention unstabl intern econom condit impact anim
busi possibl break fx impact
expect mitig effect antibiot regul potenti
regulatori environ becom challeng us intern
market mention product compar favor standard
greater opportun intern
give us updat osprey integr acquisit progress
upcom pipelin develop highlight
speak traction omnigen europ china commentari
state us dairi competit dynam
view intern market pocket strength vs weak
outlook weak vaccin driven market
quantifi exposur viginiamycin
speak consumer-driven pressur busi
across miner nutrit busi clarifi impact sale gross
margin commod price increases/decreas
updat mecadox visibl fda request
traction magni-phi poultri nutrit specialti product
divestitur perform product busi
updat aquacultur initi
could provid littl bit color loss distribut agreement
earli fiscal start lap come quarter
provid color could get back double-digit growth vaccin
nutrit specialti anyth last two quarter chang longer term
outlook busi
character underli demand trend companion anim industri
believ help return new custom growth
note relationship major manufactur
implement map price expect relationship impact price
margin long run view manufactur open altern
character evolv competit landscap new concept
thought impact chewi retail pharmaci formal on-line pet pharmaci
give color new petm reward program help
expect addit on-line marketplac entrant competit respons
exampl next gener product drove gross margin expans
signific consolid across space sever specialti brick
mortar competitor take omni-channel approach expect consolid
continu impact busi
think increment benefit gain next-gen parasiticid
flea/tick/heartworm combo benefit push sale vet channel
mobil app improv adopt trendsani impact revenu
gross margin compress recent quarter driven addit
discount off-set competit market strategi go forward
custom acquisit cost continu grow view inflect point
custom acquisit cost stabil even declin increasingli higher
advertis spend per person way sustain new custom growth
mention advertis spend rise come quarter give
us sens your spend track compar expect
advertis strategi evolv focus tv ad
success offlin advertis vs on-line updat custom acquisit cost
shift offlin advertis progress updat custom acquisit cost
offlin advertis channel market hit former ad wont
much cut term sg
activ expect chang strategi
describ on-going demand shift opportun brand gener
therapeut expect increas traction gener move forward
view role gener anim health
speak announc million invest on-line platform
improv aim drive million suffici expect increment
spend enhanc platform longer term
would character current fundament dynam product anim
busi relat contraction/expans herd size feed cost cattl feed
relev variabl think speci segment
next coupl quarter beyond overal exposur
insight consum spend trend given current macroeconom environ
industri trend see current companion anim market
posit vet util trend weve experienc sustain pet ownership trend
guidanc impli organ growth excl fx
anticip shift strategi ceo transit anticip
associ manag chang
speak strateg rational behind recent acquisit phoenix central
laboratori deal mark shift diagnost expans strategi toward
domest vs intern focu strategi lean toward similar
acquisit organ initi servic combin two
would consid ad intern refer laboratori offer
provid updat abaxi integr combin sale forc effort
report million abaxi revenu estim
maintain guidanc abaxi contribut bp oper top-lin growth
drive confid contribut legaci abaxi perform
us rel expect market
livestock diagnost opportun envis timing/magnitud
potenti upgrad instal base abaxi instrument provid
updat chemistri analyz develop well pipelin opportun
acquir smb
provid updat simparica trio approv timelin us could
label includ puppi indic beyond heartworm intern parasiticid
indic anticip
simparica trio approv europ updat
upcom launch timelin thought compet nexgard spectra
countri surpris regard approv indic
quantifi current size flea/tick/heartworm market opportun
expand market product like simparica trio cannib
speak recent launch versican bb oral new canin oral vaccin
europ product differenti thought market opportunity/s
plan launch brand gener version elan rumensin next year
anticip compet huvepharma brand gener version
competit landscap draxxin anticip gener competitor near-term
thought norbrook new gener ceftiofur embed guidanc
anticip entrant
speak market opportun proheart cannib proheart
product help round parasiticid portfolio
speak market opportun inject flea/tick/heartworm product
speak market opportun revolut cat traction-to-d
apoquel opportun aggress price product quantifi
market potenti across acut vs chronic under-penetrated
guidanc impli term atop dermat growth
veterinarian prescrib apoquel vs cytopoint level cannib
seen
thought competit landscap atop dermat view
competit threat kindr product much abl bundl
apoquel cytopoint help compet new entrant
top prioriti collabor regeneron mab
updat rimadyl competit landscap potenti offset sort
strategi take bundling/promot standpoint relat rimadyl
traction swine vaccin current market share
provid updat pharmaq underli fundament across
aquacultur opportun recent agreement pharmaq
vinh hoan vietnam
altern antibiot product explor potenti non-antibiot anti-
infect peptid stand develop process
 dollar dedic novel therapeut vs life-cycle enhanc
frame market opportun chronic felin pain critic unmet need
contribut front could peak sale potenti product go
exposure/impl african swine fever china
concern regard recent tyson ractopamin ban ractopamin
geographi see largest opportun near term companion
product anim altern area deemphas
australia see market improv near term year drought
repres increment opportun market turn
vfd compar european regul well regulatori dynam
market expos product consumer-driven pressur
gross margin go longer term driver
structur initi ahead plan progress front could
upsid downsid risk guidanc relat cost structur initi
profit differenti livestock vs companion
annual price realiz longer term sustain
open establishing/ establish direct relationship e-
commerc platform chewi thought type direct distribut
relationship impact econom map price polici
rational behind use distributor vs direct sale forc certain product
switch distribut vaccin parasiticid vs direct sale
continu abaxiss plan go direct exclus leverag
distributor dognost
distribut simparica trio direct distribut
pricing/exclus relationship larger veterinari chain distributor particularli
updat relationship corpor account
walk us two salesforc expans long take
new salesperson ramp follow expans rational expans
recent disclos sourc product manufactur
vs grey market shift occur implic busi
thought view broader implic newer concept
capit deploy opportun near term dividend hike de-lever
aggress share repurchas billion author remain
expect broader industri consolid anim continu
expect competit landscap look like near term longer term kindr
chang landscap recent merger impact creat new
opportun challeng sale forc defect
work capit improv near term address high inventori day sap
implement influenc
anticip sell-sid day decemb
give us updat underli demand trend amongst biopharma
could provid updat biotech fund environ healthy/on pace
balanc sheet
fundament demand differ across mid-siz biotech versu larg pharma
point differ significantli across differ earli stage function
discoveri safeti assess dsa
view trajectori discoveri long term describ on-going
pace progress far get better custom pull discoveri
safeti assess goal current certain custom type
inclin
provid color busi mix citoxlab fit
safeti assess discoveri busi kind custom overlap
citoxlab synergi opportun
experienc bp margin headwind relat citoxlab acquisit cost
put integr citoxlab relat previou expect
quickli think rais citoxlab op profit margin mid-teen
pace de-lever par expect
could give us updat wil perform mpi
kind util anticip new site south san francisco
particularli cradl initi expand cost estim
account cradl expans
rm supply-demand dynam look like recent research
model longer term expect perform
provid updat competit dynam within china competit
advantag leverag grow busi
think margin impact lap niaid contract
emerg competitor china rm see growth dynam
biolog could speak competit dynam specif space
long term growth opportun expect pa facil full
oper know microbi busi less capit capacity-intens
kind invest make area
volatil manufactur profit margin past quarter could
remind us lt expect segment margin profil
give us better sens cartridg pull endosaf product
quantifi volum unit price
particular therapeut area see particular strength
book other
describ natur hire initi expertis made
particularli strong hire much wage pressur see
speak vision real-tim studi data track capabl client
envis function work way see attract
near term prioriti note youd readi anoth deal
target area
type opportun would find attract china standpoint
impact recent across larger pharma sponsor bmy/celg
cybersecur breach provid updat remedi effort
client sort financi impact expect
implic recent envigo/cov transact benefit sort
interest asset
speak underli demand trend across market term custom
provid updat predict pass-through make
headway better manag quarterli expect
speak acquisit symphoni clinic research
complement pmg research meddinova research updat site network
focu shift back larg pharma vs biotech speak
associ assumpt profit
expect backlog burn
speak integr plan ahead schedul
updat site network strategi
 pipelin area focu network apac central lab expect bolt-on
strong balanc sheet consid larger transact
import leverag data improv win rate maintain data
strategi would ever think own data asset
post net-btb comment mix new busi
win base term custom size geograph area therapeut expertis
confid achiev hsd organ growth rate
speak traction recent partnership announc practic fusion ag
trend see biotech fund environ base
convers smaller biotech custom
describ broader cancel environ particularli amongst larger
biopharma custom may expos vs smaller peer
dynam see work capit account see longer payment time
custom and/or shorter payment time investig
see impact drug price rhetor washington come
discuss custom
discuss full servic vs vs hybrid model underli demand trend
favor one model custom prefer base compani size
much busi could quantifi size market
approxim rate grow faster/slow vs overal cro market
exposur pharma bmy/celg
growth past quarter slower drove weak
expect revenu continu shrink expect
non-pf growth beyond
strateg allianc repres revenu see proport
chang negoti underway line sight new
would character rfp flow experienc strength similar
broad-bas across smid larg biopharma
elabor cross-sel effort integr solut group syneo
one reson marketplac updat increment million
speak natur recent two cancel
surpris sinc inc research inventiv merger challeng
upsid surpris
confid long term hsd revenu growth target combin
entiti describ dynam segment get
experienc headwinds/tailwind relat pass through embed
speak profit margin progress long-term expect
acquisit kinaps expand offer provid
access differ type client differenti kinaps
sticki kinaps busi model clinic busi leverag
updat integr kinaps one quarter mileston sinc acquisit
stand term realiz synergi target
turnov sinc merger/cultur shift
target net leverag quarterli progress debt paydown
discuss dynam your see work capit account see
longer shorter payment time custom and/or longer/short payment time
hire progress see wage inflat
given chatter biopharmaceut space would
busi impact larg custom engag
growth area look invest move forward invest
notic slowdown biotech fund compar
impli net btb disappoint provid color
drove weak quarter impact cancel
across mix trial would breakdown recent new busi win term
size custom therapeut area fsp/full servic geographi
backlog burn declin sequenti speak underli dynam
complex clinic trial
speak larg strateg win experienc legaci commerci
custom partnership progress still expect drive revenu
speak price across industri everyon behav ration
custom concern around drug price scrutini washington reflect
pipelin decision-mak
enhanc clariti relat health industri
provid color growth differ compon within commerci
outsourc penetr stand current basi commerci
think could go next year next year
defin quantifi backlog book metric
mention target ttm net btb see
pipelin evolv second half year speak visibl
improv
growth envis stem isg
speak season see commerci segment
see increment opportun consult busi relat drug
price rhetor washington provid greater detail give sens
hear client regard
discuss underli growth rate across commerci busi
expect grow faster pace tradit cro market longer term
distinguish synh busi like iqv inventiv
histor integr commerci offer clinic offer
implic recent larg pharma bmy/celg
updat us current rfp environ recent win rate
rfp environ chang outlook see acceler
rfi convert rfp think peer see environ given
differ custom mix
think model revenu basi given volatil
pass-through quarter-to-quart project-to-project basi btb
new target
would character current smid biopharma demand biotech fund
environ given exposur segment color recent custom pipelin
sort visibl intermediate/lt goal double-digit revenu
growth initi particular expect drive
potenti opportun larg pharma custom remain
focu ampl opportun smaller biotech leverag core compet
across nich
speak current price environ everyon behav ration
differ custom segment
differ book polici compar
impact book-to-bil backlog convers metric
speak natur recent cancel expect revenu
headwind elev cancel subsid
speak natur new busi win latest quarter look
therapeut custom mix disproport larger contract
influenc new busi win
custom therapeut mix evolv next year
speak current custom concentr portion new award
come exist custom compar new custom
therapeut area focu particular categori see longer
studi start-up time complex therapeut area exposur exposur influenc
backlog convers trend seen industri constitu
discuss key differ exclus full-servic busi
model functional/piecem work full-
servic model impact growth potenti long-term margin profil
risk appetit moder think limit downsid busi
plan continu see strong book environ perhap
favor seen recent year
leverag data asset improv win rate speed start-up
competit landscap your compet new busi see
competitor tabl mayb unconvent player typic would see
specif regard larg tradit focu smid
lt target ebitda margin mind think quarterli
progress profit go speak increment invest
hire expect throughout year success gotten ahead hire
current cra retent rate contribut better profit
trend locat cincinnati hurt help
opportun improv effici across central lab busi
walk us softer margin guid gross margin sg stop
lt margin remain elev level
headcount grown y/i past four quarter trend start
taper normal hire rate look like
view fix price model cro industri specif
someth could offer futur
term central lab busi provid updat see
demand perspect extent demand growth driven core full-
servic outsourc offer invest offer
previous mention stepped-up invest central lab busi
elabor initi think fit long-term return
histor acquisit could chang
think capit deploy prioriti elimin lt debt
would ever seller obvious right price theori acquir
larger cro exclus full servic would impact busi
provid updat infrastructur invest remind us
rational make invest time
light consolid across biopharma anticip volatil across
busi would busi impact larger custom engag
dso profil current dynam differ custom segment
call indic long-term leverag ratio think
 evalu potenti opportun term size industri
provid commentari underli demand trend see
term book trend rfp volum also see chang broader
price environ competit landscap behav fairli ration moment
would character current demand trend across segment updat
competit advantag believ drive abil continu gain market
share amongst larger biopharma custom color gross book ytd
could speak underli rational behind cancel see
market would character high-risk backlog look differ
paramet mayb look histor
give us detail behind differ underli demand trend
speak exposur complex therapeut area
expect trend come quarter also lt regard
start-up time elong expect continu
earli develop busi perform
speak long term growth prospect data solut busi
seen much way disrupt relat integr cro
recent unconvent space
account standard chang impact net servic revenu
think model revenu basi given volatil pass-
through quarter-to-quart project-to-project basi
margin expect lt margin
backlog convers declin metric approach trough
expect steadi state burn rate
get drug price feedback custom
still track experi million headwind due studi delay
takeda relationship roll accord intern plan
speak custom exposur takeda etc think
shake end year time
hire updat expect expens relat elev hire normal
speak current hire environ marketplac stand
term wage salari benefit recruit cost etc
saw quit bit share volatil cro univers given announc
biopharma landscap ytd talk custom consolid gener
histor impact busi
give detail behind breakdown full servic work
larger biopharma custom see shift industri demand trend
much think mix key factor help win new busi
think help gain share
provid color revenu concentr vs larg pharma
relat symphoni rational behind buy compani
previous simpli partner would character data asset competit
posit integr offer traction
platform
effort normal symphoni revenu cadenc progress
speak perform symphoni health rel expect sinc
acquisit complet mention confer call would
consid bolt-on help drive symphoni platform elabor type
busi meet criteria
provid color extent data invest driven custom
decis make favor word data invest driven
book observ market import data
offer custom make outsourc decis
speak natur invest make much
margin upsid could provid
impli devis plan intern data asset provid
detail potenti method consid organ vs inorgan
rel healthi balanc sheet mind view current
quick recap speak key factor drove book
dynam recent quarter see book progress
speak mix new client win ytd larg vs smid biopharma
 busi perform well last quarter
take share level growth sustain
expect backlog burn trial complex
note traction core offer remain strong
million new busi quarter billion date discuss
combin data offer reson new exist custom
next gen book materi meaning top-line
speak progress roll-off biogen aducanumab trial well
recent resurrect studi expect impact nt
speak abil manag expect around volatil pass-through
contribut post-asc world
detail natur new larg pharma partnership ink combin
ta continu perform well oce meaning driver speak
broader opportun take share market relationship roch
mention larg pharma renew cycl provid opportun drive
greater uptak oce offer next month speak
strategi drive adopt would character convers
recent oce perform impact lt outlook busi
quantifi financi impact oce date lt opportun
speak overal price environ particularli
remind us medium term goal term growth rate across core
busi expect growth ramp
fund environ close tie broader biotech fund
environ see term broader demand trend
could provid updat effort continu grow faster
pace tradit full-servic demand trend sale
percent incom rfp leverag gen/cor combin offer
today percent expect next year percent rfp
appli fix price model
expect see book strength convert meaning revenu
growth acceler revenu come quarter
speak margin trend segment think profit
cadenc rest time invest
drive higher margin go forward oce effect margin
give updat traction emerg biopharma
provid updat cost save target accomplish
merger-to-d ahead plan behind plan term cost synergi
run surpris front sinc close merger
combin busi help bolster world evid offer
growth rate rwe color new real-world prefer partnership
speak driver allow csm return flat growth
see ytd track in-lin expect commit
busi trend
stand term virtual trial concept associ initi
place
term prioriti continu tuck-in deal target
area current healthi deal pipelin continu expect deal add
percentag point growth annual estim deal spend
hole fill technolog offer commerci solut busi
describ recent acquisit made ytd relat
platform updat de-lever share repurchas activ
expect meaning step capit expenditur
provid color hire initi wage inflat
see hesit across custom base concern around drug price
conjunct report note weaker expect quarterli
perform lower organ revenu ebitda growth
underli driver guidanc revis new differ rel prior
note weak august follow strong septemb experi
speak underli driver think organ
growth level expect current embed guidanc
experienc low-singl digit declin across proprietari materi
consum product group speak underli dynam impact
experi expect product group grow beyond
extent growth driven leverag vwr channel price new product launch
past coupl quarter spoken sever new custom contract win
vwr/avantor merger enhanc posit marketplac
note earn call vwr integr continu track ahead
schedul includ realiz synergi provid insight
synergi captur progress acceler pace whether potenti
increment synergi captur rel previou expect
vwr integr continu drive margin expans time
sort margin expans expect see annual much margin
expans driven oper leverag vs price strategi vs mix
help us think oper margin profil proprietari product rel
third parti product sell channel margin profil servic
high mix recur revenu revenu particularli
compar life scienc tool diagnost peer group expect
mix chang time
speak exposur key growth area biopharma market
think potenti impact biopharma custom
consolid previou transact impact contract profit
also discuss potenti implic consolid supplier side
thought pend ge biopharma transact
key driver biopharma america msd compar
histor experi region would drive growth acceler
follow ldd growth educ govern experienc msd
declin help us understand underli dynam expect
segment trend america
govern fund standpoint think current rhetor
dc thought head elect cycl
industri experi lsd declin help us understand your see
market pocket strength weak expect end-market
perform remaind year
walk us put take perform europ
quarter key driver behind strength organ growth
speak biopharma perform europ hsd underli
driver expect biopharma continu grow rang lt note cell
biolog key area strong perform help us get sens
exposur nich market
unpack perform educ govern end-market lsd
europ see fund standpoint thought
industri saw modest tighten europ lsd-msd speak
drove soft whether expect continu overal meaning
contribut industri overal geograph segment speak key driver
growth area weak
repres less total revenu ytd expect amea contribut
expand time
speak invest make five key hub india
korea/japan south east asia china east/africa amea progress
potenti run ahead/behind plan relat market
youv note meaning invest biopharma region larg
biopharma busi amea vs end market skew driven
particular market updat underli biopharma environ amea
exposur end-market healthcar educ govern
appli technolog aerospace/defens amea speak underli
environ end-market relat amea region
help us think capit deploy prioriti think
share repurchas vs debt pay vs
would consid implement dividend near longer term would
impetu initi dividend
term speak see pipelin type
deal interest ad capabl geograph expans size
deal current look remind us target leverag rang
highest level leverag comfort oper
give us updat progress ge biopharma deal well
background strateg rational expect deal still expect
close
recent announc sell million worth life scienc
busi sartori relat ge deal expect divestitur
preced deal close speak decision-mak process behind
compar integr ge pall similarities/differ synergi
departur dental proceed envista ipo
plan exit posit
structur dental transact impact remainco busi strategi
rational revis structur plan forma leverag
updat ep guidanc still includ headwind tariff
on-going initi combat impact tariff appli
give us breakdown perform geographi expect
trend remaind year drove doubl digit growth russia
europ vs singl digit growth china north america
speak mix/focu shift post-ftv spin inher
healthcare-focus recur revenu stream newer/young product line
lt margin expans target detail db oper effici
initi progress longer term nt
lt margin leverag stem
e-commerc appli busi competit
threat opportun view
global effort strategi take hold high growth market segment
see particular strength within region think
speak opportun china across sub-seg
speak polit chang dc view biggest factor
could influenc busi whether healthcar reform pama tax trade
wit market disrupt result polit uncertainti particularli
associ biolog workflow drug price rhetor dc
geographic-specif regulatori develop pay attent recent
plan report life scienc result differ post-g biopharma deal closur
break expect ge biopharma growth rate overal product line
ge guid msd organ growth biopharma busi speak
underli growth driver
call soft sciex relat refer lab/clin consolid
 give color whether think consolid
continu much pama-rel
outsid continu oper improv across pall broader life
scienc busi much recent strength attribut end market demand
trend key driver continu near term
outlin key fundament driver bioprocess single-us evolut etc
influenc life scienc segment meaning next year
youv note nih fund directli impact busi speak
exposur current demand trend fund metric correl
lt growth rate across beckman life scienc sciex leica microsystem
driver recent beckman ls strength
left term residu pall synergi integr progress
long term sustain growth rate busi
integr timelin kind ramp expect plan
expand intern outlin synergi opportun
speak product innov beckman life scienc life scienc
give us updat underli end market trend across diagnost
implic pama implement
diagnost particularli strong call driver strength
whether expect continu
molecular diagnost quantifi market opportun see china
cepheid track rel expect region view
opportun differ geographi pipelin
margin expans opportun diagnost
speak synergi fit videojet busi broader
updat industri fundament best measur busi
think long term growth rate growth profil segment hach
lt driver view idexx busi regulatori
polit environ municipal/ govern project demand trend
water pid posit sustain growth without firepow delev
plan cadenc debt paydown
tariff impact think attract variou market
labcorp america lh
give us updat underli fundament util trend across core
clinic laboratori busi expect organ volum growth trend
earli thought
manag contract speak roll horizon
bcb volum progress thu far expect
prefer lab network sort impact anticip unh new
prefer lab network lt surpris limit number lab
spoke key contract win speak expect impact
contract top-line margin perspect provid color
contract support market posit
term beacon lb pilot non-renew florida spoke
bp impact revenu per requisit associ volum
impact broadli help us understand impact across
pama quantifi headwind expect relat clinic lab
fee schedul clf incorpor anoth round repric
hospit referr volum someth structur play
help us think perform view drove
weak dtc contribut volum rel expect
expect embed guidanc given last year surpris
calendar day dynam competit landscap profit dynam
think contributor volum growth go forward
rational behind john ratliff abrupt departur recent assign ceo lcd
think medicaid rate go forward continu expect
medicaid plan reduc rate in-lin medicar reduct
updat bcb florida contract potenti win dgx/open non-
think implic commerci rate light pama
updat acla pama lawsuit
think prospect lab act term timelin
likelihood get pass explain potenti impact lab act
comment chang see hospit insourc outsourc
trend would character current pipelin
market share vs rest market trend time
view longer term normal trajectori next year
give us updat walgreen relationship store
store lt see volum consist patient servic center test mix
post ttm btb recent quarter slight improv
help us understand underli dynam
histor basi consid btb metric healthi
think assumpt chang basi
speak seen recent term biotech fund rfp
well expect
initi place acceler voluntari opt-in clinic trial databas
new busi award relat combin services/data offer
recent open new center shanghai speak success
market to-dat offer driven new busi award
speak strateg rational envigo acquisit includ
purchas envigo preclin research servic busi sale covanc
research product busi alreadi embed guidanc term
contribut transact
investor question commit preclin busi prior envigo
deal vision busi segment longer term improv
overal posit covanc
speak strateg rational behind sciformix acquisit sort
opportun see cro offer pharmacovigil regulatori
solut space see opportun bolster cro offer
youv mention trial leverag combin data asset across
covanc labcorp busi speak custom feedback
offer provid metric help us think support drug
develop process client
opportun better leverag patient servic center build walgreen
relationship virtual trial concept
your divers custom mix limit exposur speak implic
broader pharma industri consolid
provid updat launchpad initi potenti acceler
even increas cost save
expect covanc adj ebit margin reach lt
compar preclin clinic competitor
speak launchpad phase ii focus lcd segment
think potenti cost cut opportun
capit deploy vs share repo embed guidanc
 pipelin see acceler discuss relat
pressur industri pama/mco contract shift
weve posit clinic laboratori inform technolog play
commod servic provid appropri rel busi mix/futur
monet vast amount data collect cours
oper lab busi area data could provid
use synergi outsid cro space
view offer light data-driven offer
marketplac
volum price dynam
think put take organ volum growth
provid updat volum transit light
recent contract shift line potenti ahead expect
think unh/horizon volum impact much
increment volume/shar captur contract follow first full-year
access
think potenti opportun relat part unitedhealth
prefer clinic laboratori network overal intent pln
think impact longer term surpris number lab
chosen part prefer lab network
expect payor adopt prefer lab network go forward
wait see dynam larger-scal adopt could broader use
prefer network mean broader lab industri
unh prefer lab network differ previous util
criteria consid pick prefer lab provid
provid color incentiv patient physician
see increment pressur commerci insur use clf price
refer point much manag care contract essenti lock
next sever year
youv mention insur live consid in-network vs last
year would character constitu cohort
sizabl residu exclus competitor
provid updat pama relief effort progress
think introduct lab act hous
repres like pass view sens
timelin would look like
also speak acla effort pama relief effort particularli follow
submiss alca brief potenti outcom
previous experienc stepped-up patient concess earlier year
end last year patient concess trend recent
drive dynam speak y/i headwinds/tailwind experienc
thu far patient concess dynam expect impact
test denial major headwind lab busi help us think
lap denial vitamin hep etc
expect similar chang payor reimburs polici year may driver
explain reclassif bad debt vs patient concess
stand safeway partnership mani store
current partner evolv next year
expect expans safeway comfort
relationship current stand see volum loss transit shut
made progress addit basic healthcar servic youv talk
provid locat provid color point
possibl would partner addit compani part retail initi
limit safeway forese futur
speak quest direct offer help us understand better posit
market earli adopt progress custom feedback
updat site care initi innov
guid cost save year invigor program
initi progress rel expect much captur thu far
help us better understand cost save realiz across
relat potenti monet data potenti work other
pharma compani updat signific type
opportun well-posit think marketplac vs
competitor vs labcorp in-hous cro
 pipelin look like right see import
opportun pursu
recent mention deal convers timelin elong due
complex scope size deal drive convict abl
continu achiev contribut longer term
recent announc new profession lab servic pl agreement cathol
health servic long island remind us pl strategi
support overal growth strategi posit market
pipelin look like type deal
see increas pace deal progress increas potenti deal
given pama primarili hospit outreach lab space see
independ lab well
speak broadli test volum progress
element conservat full year revenu guidanc
speak recent reimburs propos hereditari cancer screen
anticip headwind reimburs pressur
speak sequenc servic offer weigh asp
speak underli demand trend across market particular
major new partnership pipelin awar
busi progress sinc licensur new york
provid color new relationship establish
recent parkinson foundat juli columbia januari stemcyt
price trend see current see pressur particular
segment competit environ anticip price degrad
come quarter
lt gross margin target break asp cost per test dynam
big salesforc anticip chang
 pipelin look speak area invest includ
probe bioinformat test offer
market product categori /or custom plan target next
genet test still earli stage adopt challeng face
compar result other
barrier reimburs competitor struggl
expand third-parti payor predominantli cash impact
approach reimburs differ peer
help us understand detail intern initi
opportun near term revenu potenti
commerci payor sign date
aspect technolog believ difficult replic cant
other thing
discuss regulatori environ affect go forward
light declin see floor
mention proactiv outsourc servic provid
speak scenario play
walk us key growth driver throughout rest year would
character fundament demand trend outlook progress
note ntp suppli issu allevi slightli thank one supplier
abil increas product capac give us updat suppli disrupt
statu supplier anticip suppli issu relat gross
margin pressur flow
give us updat pend progen deal addit color deal
rational pipelin updat expect close
updat repriorit pipelin consid addit progen
updat progen pipelin
speak competit landscap ultrasound contrast market defin
opportun extend product life-cycle
speak defin initi europ new partnership bring
defin italy/portugal/spain achiev meaning traction intern
give us updat potenti meaning chang reimburs
environ across core product line
defin rt next step defin rt complet
qualif batch remind us relationship samsung
elabor competit landscap room temperatur contrast agent
lvef note lvef indic doubl defin market opportun
walk us think size opportun speak
trial progressing/timelin
lmi fda grant orphan drug design use lmi
neuroendocrin tumor august note possibl elig rare pediatr
diseas prioriti give us updat pipelin prioriti
approv
flurpiridaz speak next develop catalyst trial enrol
quantifi market opportun
china market entri updat packaging/tri delay doubl crane
see opportun
manufactur speak on-going manufactur invest still expect
invest weight toward profit implic longer term
intern contrast ultrasound societi petit fda remov black
ultrasound contrast agent label impact demand/util trend
updat defin ip specif pertain patent expir come year
speak competit landscap molybdenum
speak ansto new facil think help
sourc suppli time
make bwxt announc abl bring technetium-
product market competit posit
speak new xenon competit entrant differ competit
entrant past relev geographi
discuss contract strategi nuclear product technelite/xenon
contract volum versu prior year
think cerevast relationship applic beyond ocular
speak impact item initi guidanc includ
onboard esrx/cigna leas account chang vaccin time
gener price visibl provid updat experienc
maintain assumpt brand price inflat msd latest
quarterli report provid updat see market
level visibl thereon
us regulatori updat think potenti implic part
 drug transit part concept specialti step therapi across
specialti busi implic propos import plan segment
busi expos
could provid updat effort implement differenti price strategi
opioid provid updat opioid litig progress
speak posit thought approach relev trail
account associ expens differ distributor potenti
opioid speak process accru conting liabil would
feel comfort enough accru
updat relationship potenti formal align
divestitur would impact
 pipelin updat focu pharma distribut relat servic vs ancillari
servic deal deal size tuck-in vs someth transform opioid
uncertainti limit flexibl
relat diversif strategi plan expand current offer
 mwi world courier servic offer expect effort
organ inorgan
diversifi profit driver percent revenu profit stem busi
outsid core distribut metric go next year
pharma segment margin declin slightli speak driver
recent under-perform trajectori thereon
concern potenti irrat sell-sid environ given recent contract
re-pric across industri
updat pharmedium
comment state contract renew current convers
custom major contract near term
heard time on-going move away contract
depend drug price inflat essenti compon overal compens
split gross profit gener drug distribut come fix
contract versu variabl correct assum pursu strategi chang
mix toward ff time
see ff agreement base total pharmaceut spend manag
manufactur profit contract still depend degre inflat even
move away contract directli tie metric think
rel import brand inflat compar abl gener
gener drug would frame two bucket term import
compar capit effici gener sourc capabl rel
competitor wbad vs red oak claruson
realiz full benefit wbad view room improv
relat gener purchas wbad
hd smith integr progress core custom group
add light acceler synergi captur rel expect forese
synergi captur opportun futur consolid opportun similar hd
speak strategy/opportun specialti defin
distribut oncolog physician-administ drug biosimilar opportun profit
dynam across busi trend next year
ebitda contribut express script express script expect
contribut revenu growth convert ebitda given
revenu lower margin
speak longer term potenti lash consult term strateg
posit top-line growth profit trajectori
provid updat progress fusion implement
factor drive implement cost higher anticip
account migrat take longer expect
anim health/mwi chang demand trend companion
product anim market expand relationship mars/woof anticip
corpor win nva
potenti implic evolv flea/tick/heartworm market us
thought direct distribut dynam particularli manufactur
broadli open altern channel chewi
implic view henri schein spin
merger vet first choic speak invest vetsourc lead
competitor covetru vet first choic platform
updat world courier growth longer term profit prospect
anticip meaning declin pharma profit -hsd dd
pars driver expect profit experi magnitud
driver think expect return profit growth core pharma
speak recent contract renew notabl chang
contract consid price line expect remind us
red oak relationship renew come due
speak gener deflat environ would character stabl
extent gener deflat headwind profit growth
would character steadi state rate gener deflat regulatori
barrier fda backlog approv influenc buy side price dynam
would say high single-digit even low double-digit deflat sustain
enough manufactur drop market rate
opportun see leverag red oak sourc jv
way add valu strateg partner besid gener
impli guidanc term overal specialti growth guidanc
assum meaning contribut biosimilar continu view biosimilar
opportun longer term
speak exposur brand drug price inflat implic lower
expect inflat environ model expect
on-going move away contract depend drug price inflat
essenti compon overal compens give us idea split
overal gross profit gener drug distribut come fix contract
versu variabl expect mix evolv go forward
think risk factor well opportun relat new
drug import propos think cardin posit regulatori
forecast lsd top-line growth medic segment
think longer term growth profil segment go forward
speak factor impact medic segment profit quarter
make feel comfort posit profit trend quarterli
season factor dynam consid
youv recent announc conduct full strateg review portfolio
provid updat thought medic busi commit
weve seen close competitor medical-surg distribut space recent face
signific pressur speak underli medic distribut growth
competit posit market
youv spoken previous commod pressur impact medic segment margin
past headwind tailwind recent quarter help us
think exposur commod pressur also step take
order mitig pressur go forward long current spot rate
typic take roll
speak charg took relat exclus distribut
agreement supplier expect similar relat charg futur
see falloff servic level exit patient recovery-rel tsa
someth plan someth particularli
surpris note known
youv mention servic level improv new initi long
take see full recoveri busi setback spill
talk cordi initi pat holt new head cordi jon giacomin
medic segment ceo type chang expect much
progress made thu far help us understand trajectori toward
profit growth end lt vision
provid updat continu suppli disrupt exam glove
expect subsid speak fundament demand trend key driver
across medic busi
divest major interest navihealth pe firm speak strateg
rational behind transact increas invest sort growth
view navihealth achiev longer term divest perceiv
provid updat progress relat search perman
cfo choos appoint interim cfo extern
speak target million gross cost save much
low hang fruit provid exampl help us think initi
entail much cost save reinvest much actual flow
cadenc
provid updat progress toward broader opioid-rel settlement
follow recent two counti settlement ohio
recent news potenti opioid settlement think capit
deploy made chang capit deploy strategi light
provid updat debt pay leverag ratio go forward time
share repurchas
think foreign currenc exposur
provid updat opioid relat headwind associ
costs/expens progress compar expect surpris
provid us view potenti impact jpm/amzn/brk ventur
busi industri gener also implic medic
thought amazon step drug suppli distribut servic chain
acquisit pillpack last year
thought around potenti impact medicar legisl drug distribut
clearli challeng among sell side appropri model
quarterli earn progress help us think move item
includ claruson rexal covermym rxcrossroad msd brand inflat
contract renewals/loss line item
speak contract renew notabl chang contract
consid price line expect associ volum
note capit deploy embed guidanc detail
capit deploy prioriti year shift strategi
term type deal interest pursu look
strengthen current busi bolt-on acquisit move new adjac size
deal
guid million opioid litig expens discuss
driver spend relat opioid epidem us also potenti canada
given expens exceed expect give confid
current estim could make expens increase/decreas
think expens beyond capit deploy flexibl
follow recent two counti settlement ohio provid updat
account opioid differ distributor
recent announc multi-year strateg initi broadli detail strateg
area focu much expect reinvest busi well
expect initi contribut lt growth target
highlight life scienc initi potenti opportun effort
entail requir increment invest cro interest
thought amazon step drug suppli distribut servic chain
acquisit pillpack view transact impact directli
think foreign currenc exposur
distributor experienc quarter better expect growth
across core us pharma distribut busi attribut larger
nation player speak dynam expect trend go
point caremark primari driver upward revenu guidanc
revis us pharma segment maintain us pharma profit outlook
help us understand underli dynam contribut impli margin
compress dynam carri forward outer year well
recent quarter discuss increment million invest
relat oncolog manufactur servic area speak specif
object invest
remind us exposur gener brand inflat averag
percent contract base trend walk us
season exposur well
speak recent greater scrutini around brand price inflat
outlook brand inflat brand inflat assumpt bake guidanc
could drive upsid downsid
gener deflat think worst behind us start see
somewhat normal possibl even recov trend
guidanc assum benefit new gener introduct
potenti impact gener current fda pipelin
youv note pleas progress initi implement
differenti price base drug class continu work contract
renew abl realiz margin benefit repric mere
partial off-set overal price headwind percentag distribut revenu
yet re-price consist strategi
healthmart stand profit driver term contribut
fast grow turnov rate franchis anoth
wholesal grow key custom segment cut opportun
youv previous mention increment opportun relat claruson
leverag scale expand new categori speak gener
perform claruson sort opportun still remain
conjunct report lower oper incom expect
european segment main driver contribut lower outlook sourc
continu pressure/relief
see remain uk market medium long-term think
better visibl across uk busi
provid updat dynam franc still see abnorm
canada also experienc meaning reimburs headwind
expect expand upon strategi mitig reimburs headwind
beyond advanc revenu diversif opportun
wholes busi perform ytd outlook thereon
speak rational behind acquisit medic specialti distributor
msd expect bolster infus offer
help us think season underli dynam medic
recent manag chang specif ed pesicka join ceo could give
us better understand strateg vision
drove appoint cfo andi long effect novemb
expect c-suit manag shift near term
speak strateg rational establish new top manag posit
includ chief commerci offic chief oper offic new
discuss stabil effort progress relat
core distribut busi discuss headwind tailwind
narrow effect lower guidanc recent quarter ex
dynam speak potenti upsid opportun risk
speak fundament demand trend domest market hospit
util volum trend track current
emphas call custom servic level improv
target speak key exampl envis opportun win
help us think potenti impact custom loss note earlier year
time impact potenti off-set
speak raw materi price dynam nitril polypropylen
product sourc level visibl maintain potenti impact
commod price chang lead time
note commod benefit potenti quantifi benefit
impact think potenti impact raw materi
beyond
halyard synergi track point still expect million
synergi april updat think
trajectori revenu halyard come quarter halyard sale forc
gain momentum expect
debt pay-down goal think time debt pay-
comfort coven point debt posit
forese need asset securit
new larg custom contract byram give us
sens natur time extent financi implic
announc renew contract vizient
announc addit extens contract chang
made either vizient want extend contract
anoth year broader strateg move anticip enter longer
provid updat progress relat rapid busi transform
program see save track million save
end
speak opportun exactli
econom work flow
updat guidanc includ headwind ep relat
revenu delay think revenu vs profit expect
previous embed guidanc rel new guid drive
go forward think fusion opportun expect
opportun ramp time
compani spoken previous opportun evolv global healthcar
servic compani connect world medic product point care
attack complex valu chain deliv enhanc valu provid
specif exampl product servic offer today may repres
growth opportun
intern medic surgic market oper differ
domest market differ opportun
substanti regulatori differ market think
impact fx intern busi
help us get understand competit landscap may evolv
domest market understand larg offer may
attract attent still see opportun continu win share
smaller region player
color employe turnov abat
compani mention price
labcorp america lh
